Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs By Investing.com
- Posted on May 1, 2025
- By Investing.com
- 2 Views
Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs By Investing.com
Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs
